Head-to-head comparison
| Property | BPC-157 | MK-677 |
|---|---|---|
| Category | Recovery | Muscle & Growth |
| Legal Status | Reclassification Pending | Unregulated |
| Primary Route | subcutaneous | oral |
| Half-life | ~4 hours (estimated) | ~24 hours |
| Mol. Weight | 1,419.53 Da | 528.67 Da |
| Side Effects | Nausea (rare), Dizziness, Headache | Increased appetite / intense hunger, Water retention and edema, Insulin resistance (glucose elevation) |
Key differences
- Chemical class: Peptides are short chains of amino acids (2–50 amino acids) that signal through diverse receptor systems; SARMs are synthetic small molecules that selectively bind androgen receptors.
- Mechanism: Peptides work through a wide variety of pathways (GH secretion, tissue repair, neuroprotection, GLP-1 signaling, etc.); SARMs specifically modulate androgen receptor activity in muscle and bone while attempting to minimize effects on prostate and liver.
- Scope: Peptides encompass hundreds of compounds across recovery, weight loss, cognitive, immune, skin, and sexual health categories; SARMs are a narrow class focused primarily on muscle growth and bone density.
- Legal status (US, 2026): Peptides have varied legal statuses—some are FDA-approved (semaglutide, PT-141), some are under reclassification review, and some are research-only. SARMs are not FDA-approved for any use and are explicitly prohibited in dietary supplements by the SARMs Control Act of 2019.
- FDA-approved examples: Multiple peptides are FDA-approved therapeutics (semaglutide, tirzepatide, PT-141, tesamorelin); zero SARMs have received FDA approval.
- Hormonal suppression: SARMs suppress natural testosterone production to varying degrees; most non-hormonal peptides (BPC-157, GHK-Cu, TB-500) do not affect the androgen axis.
- Safety data: FDA-approved peptides have extensive Phase III clinical trial data; SARMs have limited clinical data, with most human studies being Phase I or Phase II with small sample sizes.
The verdict
Peptides and SARMs are not interchangeable categories. Peptides are a broad class with diverse applications, and several are FDA-approved medications with robust clinical evidence. SARMs are a narrow class of androgen receptor modulators with no FDA approvals and significant regulatory restrictions. The risk-benefit profile differs substantially: FDA-approved peptides have established safety data, while SARMs remain investigational with limited human safety evidence and known hormonal suppression effects.
Frequently asked questions
This depends on the specific compound. FDA-approved peptides like semaglutide and tirzepatide have extensive clinical trial safety data. Research peptides without human trials (like BPC-157) have less established safety profiles. SARMs as a class have limited human safety data and are known to suppress natural testosterone production. Direct safety comparisons are compound-specific, not class-wide.
SARMs are not FDA-approved for any human use. The SARMs Control Act of 2019 placed them in the same regulatory category as anabolic steroids, making them illegal to sell as dietary supplements. They are available for legitimate research purposes but not for human consumption.
MK-677 (ibutamoren) is neither a SARM nor a peptide. It is a non-peptide, orally active ghrelin receptor mimetic that stimulates growth hormone release. It is often grouped with SARMs in online discussions because they share oral bioavailability and are sold by the same vendors, but pharmacologically it is a GH secretagogue.
Peptides that stimulate growth hormone (like ipamorelin, CJC-1295, MK-677) can support muscle growth through the GH/IGF-1 axis, but they do not directly activate androgen receptors the way SARMs do. The muscle-building effect profile is different. Peptides are not a direct replacement for androgen-mediated anabolic effects.
Most non-hormonal peptides (BPC-157, TB-500, GHK-Cu, GH secretagogues) do not suppress natural testosterone production. Some peptides that interact with the HPG axis (like GnRH analogs) can affect sex hormone levels. SARMs, by contrast, suppress testosterone production to varying degrees as a class-wide effect.